Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Meta-Analysis

Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis

Author(s): Avinash Kumar Singh, Anoop Kumar, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed and Manju Sharma*

Volume 18, Issue 2, 2023

Published on: 12 May, 2022

Page: [148 - 157] Pages: 10

DOI: 10.2174/2772432817666220315144253

Price: $65

Abstract

Background: Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear.

Aim: The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib.

Methods: The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3.

Results: A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high.

Conclusion: The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns for the CML patients treated with Imatinib.

Keywords: Hemoglobin, meta-analysis, blood cancer, tyrosine kinase inhibitors, incidence, imatinib.

[1]
Liu Z, Shi Y, Yan Z, et al. Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology 2020; 25(1): 181-5.
[http://dx.doi.org/10.1080/16078454.2020.1765563] [PMID: 32432512]
[2]
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34(4): 966-84.
[http://dx.doi.org/10.1038/s41375-020-0776-2] [PMID: 32127639]
[3]
Samal P, Chakrabarti P, Nath UK. A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia. Indian J Cancer 2019; 56(3): 211-5.
[http://dx.doi.org/10.4103/ijc.IJC_303_18] [PMID: 31389383]
[4]
Phukan A, Mandal PK, Dolai TK. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: Sharing experience of a hemato-oncology center from eastern India. Ann Hematol 2021; 100(1): 85-96.
[http://dx.doi.org/10.1007/s00277-020-04289-8] [PMID: 33025163]
[5]
Okamoto S, Ureshino H, Kawaguchi A, Miyazono M, Ikeda Y, Kimura S. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. Int J Hematol 2020; 112(1): 41-5.
[http://dx.doi.org/10.1007/s12185-020-02880-3] [PMID: 32306183]
[6]
Cesini L, Carmosino I, Breccia M, et al. Incidence of clinically significant (≤ 10 g/dL) late anemia in elderly patients with newly diagnosed chronic myeloid leukemia treated with imatinib. Oncol Res Treat 2019; 42(12): 660-4.
[http://dx.doi.org/10.1159/000502801] [PMID: 31593970]
[7]
Bauer S, Comer H, Ramsey B, Thomas K. Management of adverse events associated with tyrosine kinase inhibitor use in adult patients with chronic myeloid leukemia in chronic phase: An advanced practice perspective. J Adv Pract Oncol 2021; 12(5): 521-33.
[PMID: 34430062]
[8]
Latagliata R, Volpicelli P, Breccia M, et al. Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. Am J Hematol 2015; 90(2): 105-8.
[http://dx.doi.org/10.1002/ajh.23879] [PMID: 25349084]
[9]
Mabed M, Elhefni AM, Damnhouri G. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia. Leuk Lymphoma 2012; 53(11): 2310-1.
[http://dx.doi.org/10.3109/10428194.2012.680452] [PMID: 22462614]
[10]
Srinivas U, Pillai LS, Kumar R, Pati HP, Saxena R. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients. Am J Hematol 2007; 82(4): 314-6.
[http://dx.doi.org/10.1002/ajh.20776] [PMID: 17013815]
[11]
Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002; 31(1): 88-95.
[http://dx.doi.org/10.1093/ije/31.1.88] [PMID: 11914301]
[12]
Matti BF, Alwan AF, Alwan AF. Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: Single-center study. Turk J Haematol 2013; 30(4): 387-93.
[http://dx.doi.org/10.4274/Tjh.2012.0135] [PMID: 24385829]
[13]
Sakurai M, Kikuchi T, Karigane D, et al. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol 2019; 109(3): 292-8.
[http://dx.doi.org/10.1007/s12185-019-02596-z] [PMID: 30680668]
[14]
Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376(10): 917-27.
[http://dx.doi.org/10.1056/NEJMoa1609324] [PMID: 28273028]
[15]
Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV. Blood 2015; 126(1): 42-9.
[http://dx.doi.org/10.1182/blood-2015-01-617993] [PMID: 25918346]
[16]
Meng HT, Li Y, Jin J, Qian WB, Yang CM. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib. Ann Hematol 2007; 86(3): 231-2.
[http://dx.doi.org/10.1007/s00277-006-0218-x] [PMID: 17123082]
[17]
Kantarjian H, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer 2005; 103(10): 2099-108.
[http://dx.doi.org/10.1002/cncr.21032] [PMID: 15830345]
[18]
Yap E, Norziha ZA, Simbun A, et al. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations. Leuk Res 2017; 59: 32-40.
[http://dx.doi.org/10.1016/j.leukres.2017.05.015] [PMID: 28544907]
[19]
Li X, Cai S, Zhong Z, et al. Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report. Medicine (Baltimore) 2020; 99(9): e19256.
[http://dx.doi.org/10.1097/MD.0000000000019256] [PMID: 32118733]
[20]
Moura MS, Benevides TCL, Delamain MT, et al. Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. Hematol Transfus Cell Ther 2019; 41(4): 329-34.
[http://dx.doi.org/10.1016/j.htct.2019.03.006] [PMID: 31395459]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy